BriaCell Therapeutics Corp. (BCTX) Income Statement
BCTX FY2025 at a glance
Fiscal year ended July 31, 2025 · U.S. dollarsBCTX revenue and net income
BCTX growth rates
to FY2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BCTX quarterly EPS vs estimates
BriaCell Therapeutics beat the analyst EPS estimate in 3 of the last 5 quarters. Next report: October 21, 2026.
BCTX income statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $147,888 | $82,573 | $15,529 | $15,139 | $15,580 | $18,735 | $18,833 | $16,877 | $290 | $1,803 |
| Gross profit | −$147,888 | −$82,573 | −$15,529 | −$15,139 | −$15,580 | −$18,735 | −$18,833 | −$16,877 | −$289 | −$1,803 |
| Research & development | $29.5M | $27.2M | $20.5M | $10.3M | $2.5M | $3.0M | $4.9M | $3.1M | $2.1M | $952,150 |
| Sales, general & admin | $8.1M | $6.2M | $10.6M | $9.3M | $6.2M | $1.8M | $1.3M | $1.9M | $1.1M | $577,105 |
| Total operating expenses | $37.6M | $33.3M | $31.1M | $19.6M | $8.7M | $4.8M | $6.2M | $5.0M | $3.2M | $2.2M |
| Operating income | −$37.7M | −$33.3M | −$31.1M | −$19.6M | −$8.7M | −$5.3M | −$6.3M | −$5.0M | −$3.2M | −$2.2M |
| Interest income | — | $288,018 | $891,213 | $136,731 | $3,149 | $513 | $12,004 | $15,991 | $6,428 | — |
| Interest expense | $51,288 | — | $0 | $1,244 | $100,217 | $36,204 | $31,467 | $20,344 | $5,157 | $3,627 |
| Income before taxes | −$36.8M | −$4.9M | −$27.1M | −$34.4M | −$17.3M | −$5.4M | −$5.8M | −$5.4M | −$3.2M | −$2.2M |
| Income taxes | — | $62,852 | −$153,000 | $30,730 | $6.6M | −$72,250 | $343,743 | −$319,124 | $1,994 | $29,238 |
| Net income | −$36.5M | −$4.8M | −$27.1M | −$34.4M | −$17.3M | −$4.9M | −$5.8M | −$5.4M | −$3.2M | −$2.2M |
| EBITDA | −$37.6M | −$4.8M | −$31.1M | −$34.4M | −$17.1M | −$4.8M | −$5.8M | −$5.4M | −$3.2M | −$2.2M |
| EPS (diluted) | −$51.69 | −$36.07 | −$174.15 | −$109.10 | −$17.00 | −$510.52 | −$1127.40 | −$1447.50 | −$1073.65 | −$865.95 |
| Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | Jan '25 | Oct '24 | Jul '24 | Apr '24 | Jan '24 | Oct '23 | Jul '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $225,340 | $0 | $0 | $0 | $22,671 | $0 | $0 | $0 | $0 |
| Cost of revenue | $33,287 | $27,140 | $26,389 | $36,427 | $27,462 | $26,047 | $26,119 | $71,849 | $3,758 | $3,842 | $3,733 | $3,861 |
| Gross profit | −$33,287 | −$27,140 | −$26,389 | −$36,427 | −$27,462 | −$26,047 | −$26,119 | −$71,849 | −$3,758 | −$3,842 | −$3,733 | −$3,861 |
| Research & development | $6.0M | $8.3M | $9.4M | $9.7M | $6.6M | $8.4M | $5.1M | $6.1M | $10.5M | $11.1M | $9.4M | $6.9M |
| Sales, general & admin | $1.7M | $2.0M | $2.3M | $5.9M | $2.1M | $2.2M | $2.1M | $1.9M | $2.2M | $2.1M | $2.3M | $3.4M |
| Total operating expenses | $7.6M | $7.6M | $11.7M | $11.7M | $8.7M | $10.6M | $7.2M | $8.0M | $12.6M | $13.2M | $11.7M | $10.3M |
| Operating income | −$7.6M | −$7.7M | −$11.7M | −$11.7M | −$8.7M | −$10.6M | −$7.2M | −$8.0M | −$12.6M | −$13.2M | −$11.7M | −$10.3M |
| Interest income | $219,220 | $105,638 | $48,482 | — | $26,632 | $46,832 | $13,050 | $2 | $15,606 | $81,595 | $190,815 | $208,776 |
| Interest expense | $29,631 | — | — | — | $52,608 | — | — | — | $0 | — | — | $14.4M |
| Income before taxes | −$7.2M | −$7.4M | −$11.6M | −$11.2M | −$8.6M | −$9.3M | −$8.1M | −$1.7M | $2.3M | −$15.2M | $8.2M | −$3.2M |
| Income taxes | — | — | — | — | — | — | — | $220,429 | −$11.0M | $1.4M | −$14.5M | −$39,994 |
| Net income | −$7.2M | −$7.4M | −$11.5M | −$11.1M | −$8.5M | −$9.3M | −$8.1M | −$1.7M | $2.3M | −$15.2M | $8.3M | −$3.2M |
| EBITDA | −$7.2M | −$7.6M | −$11.6M | −$11.7M | −$8.5M | −$10.5M | −$7.1M | −$7.9M | $2.3M | −$13.2M | −$11.7M | −$3.2M |
| EPS (diluted) | −$0.99 | −$2.58 | −$4.35 | $0.04 | −$16.40 | −$2.33 | −$33.00 | −$0.07 | $16.50 | −$106.50 | $54.00 | −$0.15 |
| Gross margin | — | — | — | −16.2% | — | — | — | −316.9% | — | — | — | — |
| Operating margin | — | — | — | −5,187.6% | — | — | — | −35,319.1% | — | — | — | — |
| Net margin | — | — | — | −4,906.9% | — | — | — | −7,434.7% | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BCTX's financial statements (latest annual report filed October 16, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BCTX financial results
BriaCell Therapeutics reported no revenue in fiscal year 2025 (ended July 31, 2025). It had a net loss of $36.5 million. Diluted earnings per share came to −$51.69.
See the BCTX stock overview for the latest quote and news, or the BCTX chart for price history and technical indicators.
BCTX income statement FAQ
Does BriaCell Therapeutics have revenue?
BriaCell Therapeutics reported no revenue for fiscal year 2025, which ended on July 31, 2025.
Is BriaCell Therapeutics profitable?
No. BriaCell Therapeutics reported a net loss of $36.5 million in fiscal 2025.
How much does BriaCell Therapeutics spend on research and development?
BriaCell Therapeutics spent $29.5 million on research and development in fiscal 2025.
What are BriaCell Therapeutics's earnings per share?
BriaCell Therapeutics earned $-51.69 per diluted share in fiscal 2025, compared with $-36.07 a year earlier.
When will BriaCell Therapeutics report its next earnings?
BriaCell Therapeutics is expected to report results for the quarter ending July 31, 2026 on October 21, 2026.
When does BriaCell Therapeutics's fiscal year end?
BriaCell Therapeutics's fiscal year ends in July. The latest annual report covers the year ended July 31, 2025 and was filed on October 16, 2025.